argenx announced positive topline results from its Phase 2 trial of FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The study met its primary endpoint, showing FB102 significantly prevented gluten-induced intestinal damage compared to placebo. The drug demonstrated consistent efficacy across histologic, inflammatory, and clinical measures, with a safety profile in line with previous studies. These promising results support argenx's plan to advance FB102 into Phase 3 trials, aiming to address the unmet need for celiac disease treatments beyond a gluten-free diet.
argenx's Phase 2 trial results in celiac disease provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 08, 2026 12:11 WIB: out of 100 priced health-sector US stocks, 44 rose and 52 fell. Notable movers include ABEO at USD 5.18 with a 3.39% gain, TDOC at USD 5.58 with a 3.38% loss, and ADPT at USD 26.16 with a 2.75% loss.
FLSmidth secured a DKK 360 million contract to supply advanced crushing and grinding equipment for a copper mine expansion in Northern Chile. The order includes the world's largest gyratory crusher, a large SAG mill, and three ball mills, with instal...
On October 8, 2026, Michelin repurchased 202,417 of its own ordinary shares at a weighted average price of €32.33 per share through over-the-counter transactions. The shares bought back are intended for cancellation, which can reduce the total number...
On October 8, 2026, Michelin executed a share buyback, purchasing 202,417 ordinary shares at a weighted average price of €32.33 per share. The shares were acquired through over-the-counter transactions involving several financial institutions and are...
FORVIA HELLA has secured two significant series orders for its EnergyCore solutions, including its first 3-in-1 high-voltage battery management system and a 48-volt PowerPack. These integrated systems reduce vehicle cost, complexity, weight, and spac...
Bavarian Nordic A/S has upgraded its financial outlook for 2026 due to stronger-than-expected sales in its Travel Health segment, particularly driven by increased demand for rabies vaccines in the U.S. amid rising rabies exposure. The company now exp...
